Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCS.
Page 6: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1501 | 0 | 0 | 1328 2002 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
1502 | 0 | 0 | 1329 2002 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
1503 | 0 | 0 | 1330 2002 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
1504 | 0 | 0 | 1331 2002 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
1505 | 0 | 0 | 1332 2002 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
1506 | 0 | 0 | 1333 2002 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
1507 | 0 | 0 | 1334 2002 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
1508 | 0 | 0 | 1335 2002 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
1509 | 0 | 0 | 1336 2002 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 3 |
1510 | 0 | 0 | 1337 2002 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1511 | 0 | 0 | 1338 2002 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
1512 | 0 | 0 | 1339 2002 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
1513 | 0 | 0 | 1340 2002 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
1514 | 0 | 0 | 1341 2002 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
1515 | 0 | 0 | 1342 2002 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
1516 | 0 | 0 | 1343 2002 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
1517 | 0 | 0 | 1344 2002 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
1518 | 0 | 0 | 1345 2002 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
1519 | 0 | 0 | 1346 2002 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
1520 | 0 | 0 | 1347 2002 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1521 | 0 | 0 | 1348 2002 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |
1522 | 0 | 0 | 1349 2002 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
1523 | 0 | 0 | 1350 2002 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
1524 | 0 | 0 | 1351 2002 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
1525 | 0 | 0 | 1352 2002 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
1526 | 0 | 0 | 1353 2002 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
1527 | 0 | 0 | 1354 2002 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
1528 | 0 | 0 | 1355 2002 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
1529 | 0 | 0 | 1356 2002 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
1530 | 0 | 0 | 1357 2002 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1531 | 0 | 0 | 1358 2002 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
1532 | 0 | 0 | 1359 2002 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
1533 | 0 | 0 | 1360 2002 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
1534 | 0 | 0 | 1361 2002 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
1535 | 0 | 0 | 1362 2002 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
1536 | 0 | 0 | 1363 2002 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
1537 | 0 | 0 | 1364 2002 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
1538 | 0 | 0 | 1365 2002 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
1539 | 0 | 0 | 1366 2002 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
1540 | 0 | 0 | 1367 2002 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1541 | 0 | 0 | 1368 2002 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
1542 | 0 | 0 | 1369 2002 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
1543 | 0 | 0 | 1370 2002 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 4 |
1544 | 0 | 0 | 1371 2002 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
1545 | 0 | 0 | 1372 2002 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
1546 | 0 | 0 | 1373 2002 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
1547 | 0 | 0 | 1374 2002 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
1548 | 0 | 0 | 1375 2002 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
1549 | 0 | 0 | 1376 2002 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 5 |
1550 | 0 | 0 | 1377 2002 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1551 | 0 | 0 | 1378 2002 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
1552 | 0 | 0 | 1379 2002 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
1553 | 0 | 0 | 1380 2002 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
1554 | 0 | 0 | 1381 2002 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
1555 | 0 | 0 | 1382 2002 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
1556 | 0 | 0 | 1383 2002 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
1557 | 0 | 0 | 1384 2002 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
1558 | 0 | 0 | 1385 2002 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
1559 | 0 | 0 | 1386 2002 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
1560 | 0 | 0 | 1387 2002 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1561 | 0 | 0 | 1388 2002 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
1562 | 0 | 0 | 1391 2002 BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
1563 | 0 | 0 | 1392 2002 BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
1564 | 0 | 0 | 1393 2002 BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
1565 | 0 | 0 | 1396 2002 BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
1566 | 0 | 0 | 1397 2002 BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
1567 | 4 | 6 | 1399 2002 BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
1568 | 4 | 5 | 1401 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
1569 | 3 | 5 | 1404 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275 Pitini V; Teti D; Arrigo C; Aloi G Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF | 0 | 0 |
1570 | 0 | 4 | 1405 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 3 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1571 | 6 | 7 | 1406 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |
1572 | 9 | 9 | 1407 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305 Eter N; Spitznas M DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture | 0 | 0 |
1573 | 1 | 9 | 1408 2002 BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
1574 | 0 | 2 | 1409 2002 BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
1575 | 5 | 5 | 1410 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
1576 | 16 | 29 | 1413 2002 CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
1577 | 19 | 51 | 1416 2002 CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
1578 | 0 | 0 | 1418 2002 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
1579 | 2 | 18 | 1419 2002 CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
1580 | 8 | 16 | 1422 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44 Seyahi E; Ozdogan H; Masatlioglu S; Yazici H Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient | 0 | 4 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1581 | 14 | 18 | 1424 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
1582 | 1 | 9 | 1426 2002 CLINICAL CANCER RESEARCH 8(8):2750-2750 Go RS; Horstman AL Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. | 0 | 0 |
1583 | 0 | 6 | 1427 2002 CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
1584 | 0 | 0 | 1430 2002 CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
1585 | 0 | 0 | 1431 2002 CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
1586 | 57 | 82 | 1432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
1587 | 10 | 26 | 1435 2002 DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
1588 | 6 | 6 | 1436 2002 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
1589 | 0 | 0 | 1438 2002 DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
1590 | 3 | 34 | 1439 2002 DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1591 | 0 | 0 | 1441 2002 EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
1592 | 0 | 0 | 1442 2002 EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
1593 | 8 | 23 | 1446 2002 EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
1594 | 0 | 0 | 1447 2002 EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
1595 | 0 | 0 | 1448 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
1596 | 0 | 0 | 1449 2002 EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
1597 | 7 | 18 | 1450 2002 FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
1598 | 0 | 0 | 1451 2002 FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
1599 | 0 | 0 | 1452 2002 FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
1600 | 0 | 0 | 1454 2002 GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1601 | 0 | 0 | 1455 2002 GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
1602 | 14 | 22 | 1462 2002 HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
1603 | 1 | 8 | 1465 2002 HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
1604 | 2 | 2 | 1466 2002 HAUTARZT 53(2):150-151 Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement | 0 | 0 |
1605 | 0 | 0 | 1469 2002 INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
1606 | 0 | 0 | 1470 2002 INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
1607 | 0 | 0 | 1471 2002 INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
1608 | 7 | 20 | 1473 2002 INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369 Miller S; Sharda S; Rodrigue J; Mehta P Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life | 0 | 0 |
1609 | 4 | 40 | 1477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
1610 | 10 | 19 | 1482 2002 JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1611 | 2 | 4 | 1484 2002 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
1612 | 1 | 1 | 1489 2002 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002) | 0 | 0 |
1613 | 10 | 21 | 1491 2002 JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
1614 | 10 | 18 | 1493 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
1615 | 0 | 0 | 1497 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
1616 | 0 | 0 | 1501 2002 JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
1617 | 2 | 32 | 1503 2002 JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
1618 | 4 | 40 | 1505 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
1619 | 10 | 22 | 1506 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
1620 | 0 | 0 | 1508 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1621 | 7 | 15 | 1509 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
1622 | 7 | 10 | 1510 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
1623 | 0 | 0 | 1511 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
1624 | 0 | 0 | 1512 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
1625 | 3 | 16 | 1513 2002 JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
1626 | 0 | 1 | 1514 2002 JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
1627 | 0 | 0 | 1515 2002 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
1628 | 0 | 0 | 1516 2002 LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
1629 | 11 | 20 | 1524 2002 LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
1630 | 2 | 2 | 1528 2002 MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Rajkumar SV; Gertz MA; Kyle RA; Greipp PR Thalidomide-induced neuropathy - In reply | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1631 | 0 | 0 | 1533 2002 NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
1632 | 18 | 28 | 1537 2002 ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
1633 | 1 | 4 | 1538 2002 ONCOLOGY-NEW YORK 16(3):276-+ Phuphanich S Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy | 0 | 0 |
1634 | 3 | 5 | 1540 2002 ONCOLOGY-NEW YORK 16(9):1146-+ Leibowitz R; Tucker SJ PSA response to thalidomide in patients with advanced prostate cancer | 0 | 0 |
1635 | 53 | 61 | 1541 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
1636 | 2 | 25 | 1542 2002 PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
1637 | 0 | 0 | 1547 2002 PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
1638 | 5 | 25 | 1548 2002 RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
1639 | 0 | 83 | 1552 2002 SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
1640 | 20 | 32 | 1555 2002 THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1641 | 0 | 0 | 1556 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U196-U197 Hu ZG; Pandit B; Shi JD; Zink J; Sackett DL; Li PK Thalidomide analogs with antiproliferative and antimicrotubule activities. | 0 | 0 |
1642 | 0 | 0 | 1557 2003 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U197-U197 Luzzio FA; Ng SSW; Gutschow M; Hauschildt S; Weiss M; Teubert U; Kruger E; Mayorov AV; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs. | 0 | 0 |
1643 | 2 | 8 | 1558 2003 ACTA DERMATO-VENEREOLOGICA 83(4):302-303 Staumont-Salle D; Magro L; Piette F; Thomas P; Jouet JP; Catteau B Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide | 0 | 0 |
1644 | 5 | 9 | 1559 2003 ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
1645 | 8 | 11 | 1560 2003 ADAMANTIADES-BEHCET'S DISEASE 528:585-589 Sohn S; Lee ES; Lee SI; Kim YA; Kwon HJ; Bang D; Lei S Therapeutic effect of thalidomide through cytokine and chemokine regulation in herpes simplex virus-induced Behcet's disease-like animal model | 0 | 0 |
1646 | 7 | 31 | 1561 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
1647 | 11 | 28 | 1562 2003 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
1648 | 43 | 65 | 1563 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
1649 | 3 | 10 | 1566 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(3):205-207 Barton JC Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia | 0 | 0 |
1650 | 1 | 5 | 1567 2003 AMERICAN JOURNAL OF HEMATOLOGY 74(4):290-291 Gomez-Rangel JD; Ruiz-Delgadoz GJ; Ruiz-Arguelles GJ Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myelorna receiving thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1651 | 0 | 0 | 1568 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):197-197 Kohlhase J; Schubert L; Liebers M; Hennekam RCM; Rauch A; Becker K; Mohammed SN; Wright M; Hannibal MC; Newbury-Ecob R; Reardon W SALL4 mutations result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, Acro-Reno-Ocular syndrome and patients previously reported to represent Thalidomide Embryopathy. | 0 | 0 |
1652 | 0 | 0 | 1569 2003 AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
1653 | 1 | 10 | 1570 2003 AMERICAN JOURNAL OF MEDICINE 115(4):332-334 Staak JO; Glossmann JP; Esser JM; Diehl V; Mietz H; Josting A Thalidomide for systemic capillary leak syndrome | 0 | 0 |
1654 | 8 | 13 | 1571 2003 AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS 10(4):257-261 Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Witzig TE; Fonseca R; Lust JA; Greipp PR; Kyle RA; Gertz MA Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis | 0 | 0 |
1655 | 5 | 6 | 1572 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
1656 | 4 | 19 | 1573 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1109-1112 Macario-Barrel A; Balguerie X; Joly P Treatment of erosive oral lichen planus with thalidomide | 0 | 0 |
1657 | 1 | 1 | 1574 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1187-1187 Schmutz JL; Barbaud A; Trechot P Thalidomide: the first case with gynecomastia | 0 | 0 |
1658 | 2 | 5 | 1575 2003 ANNALS OF HEMATOLOGY 82(4):262-262 Ribatti A; Vacca A On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma | 0 | 0 |
1659 | 27 | 37 | 1576 2003 ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
1660 | 9 | 33 | 1577 2003 ANNALS OF HEMATOLOGY 82(10):654-659 Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IGD; Martin H; Hoelzer D; Ho AD; Lokhorst HM Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1661 | 10 | 33 | 1579 2003 ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
1662 | 12 | 27 | 1583 2003 ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
1663 | 6 | 17 | 1584 2003 ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
1664 | 14 | 24 | 1585 2003 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
1665 | 7 | 17 | 1586 2003 APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
1666 | 10 | 16 | 1587 2003 ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX 96(10):1006-1010 Jego C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV Left atrial thrombus in the course of multiple myeloma treated with thalidomide | 0 | 0 |
1667 | 13 | 25 | 1589 2003 ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
1668 | 2 | 7 | 1590 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
1669 | 1 | 1 | 1591 2003 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
1670 | 0 | 4 | 1592 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1671 | 1 | 5 | 1593 2003 ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
1672 | 0 | 0 | 1594 2003 ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
1673 | 0 | 0 | 1595 2003 ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
1674 | 0 | 0 | 1596 2003 ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
1675 | 0 | 0 | 1597 2003 ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
1676 | 0 | 0 | 1598 2003 ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
1677 | 0 | 0 | 1599 2003 BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
1678 | 0 | 0 | 1601 2003 BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
1679 | 0 | 4 | 1603 2003 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
1680 | 0 | 0 | 1605 2003 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1681 | 0 | 0 | 1606 2003 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
1682 | 0 | 0 | 1607 2003 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 1 |
1683 | 0 | 0 | 1608 2003 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
1684 | 0 | 0 | 1609 2003 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
1685 | 0 | 0 | 1610 2003 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 4 |
1686 | 0 | 0 | 1611 2003 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
1687 | 0 | 0 | 1612 2003 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
1688 | 0 | 0 | 1613 2003 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
1689 | 0 | 0 | 1614 2003 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
1690 | 0 | 0 | 1615 2003 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1691 | 0 | 0 | 1616 2003 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
1692 | 0 | 0 | 1617 2003 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
1693 | 0 | 0 | 1618 2003 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
1694 | 0 | 0 | 1619 2003 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
1695 | 0 | 0 | 1620 2003 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
1696 | 0 | 0 | 1621 2003 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
1697 | 0 | 0 | 1622 2003 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
1698 | 0 | 0 | 1623 2003 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
1699 | 0 | 0 | 1624 2003 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
1700 | 0 | 0 | 1625 2003 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1701 | 0 | 0 | 1626 2003 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
1702 | 0 | 0 | 1627 2003 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
1703 | 0 | 0 | 1628 2003 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
1704 | 0 | 0 | 1629 2003 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
1705 | 0 | 0 | 1630 2003 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
1706 | 0 | 0 | 1631 2003 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
1707 | 0 | 0 | 1632 2003 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
1708 | 0 | 0 | 1633 2003 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
1709 | 0 | 0 | 1634 2003 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
1710 | 0 | 0 | 1635 2003 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1711 | 0 | 0 | 1636 2003 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
1712 | 0 | 0 | 1637 2003 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
1713 | 0 | 0 | 1638 2003 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
1714 | 0 | 0 | 1639 2003 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
1715 | 0 | 0 | 1640 2003 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
1716 | 0 | 0 | 1641 2003 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
1717 | 0 | 0 | 1642 2003 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
1718 | 0 | 0 | 1643 2003 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
1719 | 0 | 0 | 1644 2003 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
1720 | 0 | 0 | 1645 2003 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1721 | 0 | 0 | 1646 2003 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
1722 | 0 | 0 | 1647 2003 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
1723 | 0 | 0 | 1648 2003 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 1 |
1724 | 0 | 0 | 1649 2003 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
1725 | 0 | 0 | 1650 2003 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
1726 | 0 | 0 | 1651 2003 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
1727 | 0 | 0 | 1652 2003 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
1728 | 0 | 0 | 1653 2003 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 1 |
1729 | 0 | 0 | 1654 2003 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |
1730 | 0 | 0 | 1655 2003 BLOOD 102(11):692A-692A Moehler T; Hillengass J; Gerull S; Benner A; Schlenzka J; Neben K; Egerer G; Schaefer H; Goerner M; He AD Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1731 | 0 | 0 | 1656 2003 BLOOD 102(11):829A-830A Lentzsch S; Koh KR; Stirling D; Zenke M; Dorken B Immunomodulatory derivative of thalidomide (IMiD CC-4047) determine the lineage commitment of hematopoietic progenitors by down regulation of GATA-1 and modulation of cytokine secretion. | 0 | 0 |
1732 | 0 | 0 | 1657 2003 BLOOD 102(11):903A-903A Mitsiades CS; Mitsiades N; McMullan CJ; Poulaki V; Shringarpure R; Hideshima T; Chauhan D; Treon SP; Richardson PG; Munshi NC; Joseph M; Libermann TA; Anderson KC Immunomodulatory thalidomide derivatives have activity against tumor cells from Waldenstrom's macroglobulinemia. | 0 | 0 |
1733 | 0 | 0 | 1658 2003 BLOOD 102(11):923A-924A Elliott MA; Geyer SM; Camoriano JK; Kahanic SP; Alexander SJ; Medgyesy DC; Li CY; Tefferi A Low dose thalidomide (Td) treatment in myelofibrosis with myeloid metaplasia (MMM): An NCCTG study. | 0 | 0 |
1734 | 0 | 0 | 1659 2003 BLOOD 102(11):938A-938A Anagnostopoulos A; Zervas K; Zomas A; Pouli A; Hamilos G; Anagnostopoulos N; Dimopoulos MA The International Prognostic Index (IPI) is predictive for survival in refractory or relapsed myeloma patients treated with thalidomide-based regimens. | 0 | 0 |
1735 | 0 | 0 | 1660 2003 BLOOD 102(11):984A-984A Sahebi F; Somlo G; Kogut NM; Falk PM; Spielberger R; Parker PM; Krishnan A; Frankel P; Kosobayashi N; Forman SJ Feasibility and toxicity of maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma | 0 | 0 |
1736 | 0 | 0 | 1661 2003 BLOOD 102(11):985A-986A Somlo G; Yamamoto N; Carter N; O'Donnell M; Snyder D; Sahebi F; Krishnan A; Fung H; Stein A; Spielberger R; Schriber J; Alvarnas J; Chow W; Nademance A; Jasmine Z; Stephen F High complete response rate is associated with improved progression-free and overall survival in 104 patients with multiple myeloma, treated with tandem cycle high-dose melphalan and busulfan/cytoxan, and maintenance interferon alpha-2 (IF) with, or without thalidomide (Thai) | 0 | 0 |
1737 | 0 | 0 | 1662 2003 BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
1738 | 0 | 0 | 1663 2003 BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
1739 | 2 | 6 | 1664 2003 BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
1740 | 0 | 1 | 1665 2003 BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1741 | 6 | 6 | 1667 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
1742 | 0 | 0 | 1669 2003 BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
1743 | 0 | 0 | 1670 2003 BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
1744 | 4 | 9 | 1672 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
1745 | 5 | 11 | 1673 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
1746 | 0 | 0 | 1674 2003 BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
1747 | 11 | 14 | 1675 2003 BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
1748 | 1 | 1 | 1685 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
1749 | 1 | 3 | 1686 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
1750 | 0 | 3 | 1687 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1751 | 0 | 1 | 1688 2003 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
1752 | 5 | 27 | 1690 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
1753 | 0 | 0 | 1691 2003 CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
1754 | 4 | 39 | 1694 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
1755 | 0 | 0 | 1696 2003 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
1756 | 4 | 12 | 1697 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
1757 | 0 | 0 | 1699 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
1758 | 8 | 8 | 1700 2003 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
1759 | 0 | 0 | 1701 2003 CLINICAL CANCER RESEARCH 9(16):6150S-6150S Baas P; Haringhuizen A; Boogerd W; Dalesio O; Van Zandwijk N Thalidomide in malignant pleural mesothelioma: Results of a phase II study. | 0 | 0 |
1760 | 9 | 21 | 1703 2003 CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1761 | 0 | 0 | 1705 2003 CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
1762 | 13 | 38 | 1708 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
1763 | 2 | 3 | 1711 2003 DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
1764 | 5 | 10 | 1714 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
1765 | 0 | 0 | 1715 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
1766 | 0 | 0 | 1716 2003 EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
1767 | 12 | 33 | 1717 2003 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
1768 | 1 | 6 | 1718 2003 EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
1769 | 0 | 0 | 1719 2003 EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
1770 | 0 | 0 | 1721 2003 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1771 | 0 | 0 | 1722 2003 GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
1772 | 0 | 0 | 1723 2003 GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
1773 | 0 | 0 | 1724 2003 GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
1774 | 3 | 10 | 1725 2003 HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
1775 | 4 | 10 | 1726 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
1776 | 4 | 10 | 1727 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
1777 | 6 | 15 | 1728 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
1778 | 16 | 42 | 1730 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
1779 | 11 | 39 | 1731 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
1780 | 6 | 40 | 1732 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1781 | 7 | 20 | 1733 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
1782 | 13 | 23 | 1735 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 23(6):1651-1655 Kaicker S; McCrudden KW; Beck L; New T; Huang JZ; Frischer JS; Serur A; Kadenhe-Chiweshe A; Yokoi A; Kandel JJ; Yamashiro DJ Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma | 0 | 0 |
1783 | 4 | 9 | 1737 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
1784 | 0 | 0 | 1738 2003 JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
1785 | 57 | 70 | 1739 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
1786 | 6 | 15 | 1741 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
1787 | 7 | 12 | 1748 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
1788 | 10 | 16 | 1749 2003 JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
1789 | 19 | 40 | 1750 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
1790 | 9 | 42 | 1751 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
1791 | 10 | 26 | 1756 2003 JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 1 |
1792 | 4 | 4 | 1757 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
1793 | 2 | 5 | 1758 2003 JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 1 |
1794 | 2 | 29 | 1759 2003 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
1795 | 19 | 32 | 1762 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
1796 | 9 | 12 | 1764 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
1797 | 11 | 52 | 1765 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
1798 | 0 | 0 | 1766 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
1799 | 0 | 0 | 1767 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
1800 | 8 | 12 | 1770 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |